On the fly News and insights, exclusive to thefly.com



$11.25 /

+0.12 (+1.08%)


Cantor sees 'golden egg' potential in Dermira, boosts price target to $25

Cantor Fitzgerald analyst Louise Chen raised her price target for Dermira to $25 from $20 and reiterates an Overweight rating on the shares. The stock in afternoon trading is up 14c to $11.27. Peak sales potential of Qbrexza for hyperhidrosis and lebrikizumab for atopic dermatitis are underappreciated, Chen tells investors in a research note ahead of the long Easter weekend titled "We Think This Bunny Could Lay The Golden Egg." The analyst also thinks Dermira is an "interesting company in a consolidating space." Her new price target reflects the inclusion of Lebrikizumab sales following the positive Phase 2b data readout earlier this year.

  • 06


DERM Dermira
$11.25 /

+0.12 (+1.08%)

04/18/19 Cantor Fitzgerald
Dermira price target raised to $25 from $20 at Cantor Fitzgerald
03/27/19 H.C. Wainwright
Dermira price target raised to $22 from $13 at H.C. Wainwright
03/25/19 Needham
Dermira price target raised to $22 from $16 at Needham
03/21/19 Mizuho
Dermira price target raised to $17 from $10 at Mizuho

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.